Getein Biotech, Inc. Class A

Getein Biotech, Inc. Class A

SSSE:603387
8.26
CNY
+0.06
(+0.73%)
0.58EPS
17.33P/E
5.08BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.55
0.73
0.97
1.13
1.35
1.91
2.21
2.78
3.58
2.69
2.29
2.1
2.2
Basic EPS, GAAP
0.17
0.2
0.28
0.36
0.45
0.49
0.67
0.6
0.79
0.98
0.55
0.44
0.44
0.58
Free Cash Flow per Basic Share
- -
0.07
0.2
0.31
0.3
0.15
0.2
0.14
0.5
0.52
0.15
0.52
0.48
- -
Dividend per Share
0.06
0.03
0.02
0.16
0.16
0.12
0.15
0.23
0.21
0.28
0.43
0.22
0.21
0.33
Book Value per Share
0.22
0.43
0.7
0.89
2.25
2.65
3.18
3.6
4.14
4.89
5.05
5.16
5.43
5.73
Tangible Book Value per Share
0.2
0.4
0.65
0.83
2.2
2.59
3.11
3.39
3.88
4.56
4.64
4.79
5.01
5.32
Basic Weighted Avg Shares
380
380
381
380
433
510
508
508
505
509
509
508
502
506
Sales/Revenue/Turnover
154
210
276
369
489
686
968
1,123
1,402
1,822
1,369
1,165
1,052
1,114
Operating Margin (%)
44.97
38.21
39.83
40.44
44.1
36.74
39.06
30.92
31.13
30.47
19.59
23.66
24.44
27.61
Depreciation Expense
- -
7
10
16
21
25
28
36
49
70
93
94
85
- -
Net Income, GAAP
66
75
105
138
194
250
340
305
399
499
280
224
221
293
Effective Tax Rate (%)
13.28
16.2
14.76
14.44
13.47
12.75
11.62
11.69
8.77
10.01
6.84
9.29
6.93
9.12
Profit Margin (%)
42.56
35.73
38.01
37.49
39.7
36.37
35.08
27.13
28.46
27.38
20.43
19.2
20.98
26.25
Working Capital
15
62
143
194
939
1,108
1,250
1,459
1,552
1,441
1,172
917
1,448
1,824
LT Debt
- -
- -
- -
- -
- -
- -
- -
22
30
8
3
2
1
1
Total Equity
84
165
269
343
1,148
1,388
1,682
2,004
2,274
2,665
2,741
2,721
2,859
3,011
Return on Invested Capital (%)
91.03
52.36
42.28
40.59
25.29
19.14
22.04
15.91
15.98
16.91
8.66
7.08
6.62
8.64
Return on Capital (%)
105.16
60.75
48.57
45.16
25.88
19.35
20.9
13.65
15.46
16.89
8.74
6.88
7.24
8.87
Return on Common Equity (%)
106.15
61.06
49.04
45.62
26.15
20.02
22.83
17.6
20.23
21.74
11.1
8.64
8.22
10.47

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
400
341
276
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
507
507
507
Market Capitalization
5,082
3,834
5,077

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,318
2,561
2,467
Cash, Cash Equivalents & STI
1,358
1,680
1,664
Accounts Receivable, Net
326
333
310
Inventories
196
189
193
Total Current Liabilities
722
681
643
Payables & Accruals
- -
- -
- -
ST Debt
400
341
276
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.15%
7.58%
5.09%
Free Cash Flow
45.97%
86.1%
-9.22%
Net Income, GAAP
11.7%
-1.87%
-1.33%
Sales/Revenue/Turnover
16.87%
1.05%
-9.71%
Total Cash Common Dividend
63.84%
4.96%
-6.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
322
296
262
285
1,165
2025
244
269
- -
294
1,052
2026
268
288
265
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.12
0.06
0.1
0.44
2025
0.13
0.09
- -
0.12
0.44
2026
0.15
0.21
0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.1
0.1
0.01
0.22
2025
- -
0.1
- -
0.01
0.21
2026
- -
0.15
0.16
- -
- -

Company Description

CEO
En Ben Su
Full Time Employees
1,733
Sector
Health technology
Industry
Biotechnology
Address
No.9 Bofu Road Nanjing JS China 211505
IPO Date
Jul 17, 2017
Business
Getein Biotech, Inc. (603387.SS) researches, develops, manufactures, markets and distributes in vitro diagnostic (IVD) reagents, instruments and analytical medical devices with a focus on point-of-care testing (POCT). The company offers fluorescence immunoassay analyzers and test kits for cardiac markers such as troponin I; chemiluminescence immunoassay systems; clinical chemistry analyzers and reagents; molecular diagnostic kits; thrombus and hemostasis detection products; blood cell analyzers; urine analysis systems; quality control products; and diagnostic raw materials, spanning detection fields including cardiovascular diseases, inflammation, kidney injury, thyroid function, hormones, glucose metabolism, tumors, infectious diseases and coagulation. Getein Biotech, Inc. serves laboratories, emergency rooms, health examination centers, community clinics and personal health management applications primarily in China and internationally across more than 110 countries and territories. Founded in 2002 and headquartered in Nanjing, Jiangsu Province, China, the company maintains leading market share in China's cardiac POCT segment and operates 35 subsidiaries. In recent developments, Getein Biotech showcased advanced diagnostic solutions at the Global Health Exhibition 2025 in Riyadh from October 27-30 and hosted a distributor partners meeting in Antalya, Turkey, on October 29 to strengthen international presence; it continues expansion through OEM/ODM services and certifications including ISO13485 and CE.